...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Phase 3 BETonMACE Trial is Now Completed. Cognition and CKD Sub-Study Results to be Announced Soon.

Free
Message: Re: New Share Price Contest update to Oct 12th

I agree it’s likely the CVD, CKD and cognitive outcomes will be presented at different meetings for two reasons. First, the academics have devoted a lot of time and effort to BETonMACE, and they will want to get as many congress presentations and published papers out of it as possible. Secondly, each of the three areas is highly specialised, and the results need to be considered by experts in each field. Therefore, IMO the AHA is likely to focus on CVD alone.

Share
New Message
Please login to post a reply